STD Diagnostics Global Market Report 2024 - By Size, Share, Report, Demand, Outlook By 2033

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2709

The Business Research Company offers in-depth market insights through STD Diagnostics Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The std diagnostics market size has grown rapidly in recent years. It will grow from $9.25 billion in 2023 to $10.19 billion in 2024 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to epidemiological trends, healthcare infrastructure development, pharmaceutical developments, sexual education programs, demographic shifts..

The std diagnostics market size is expected to see strong growth in the next few years. It will grow to $14.82 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to personalized medicine trends, healthcare access improvements, population health strategies, telemedicine and digital health, rising incidence of stds.. Major trends in the forecast period include point-of-care testing (poct) advancements, home testing kits,multiplex testing, targeted marketing and outreach, pre-exposure prophylaxis (prep) programs, rising incidence rates..

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=8507&type=smp

Market Segmentation:
The std diagnostics market covered in this report is segmented -
1) By Type: Chlamydia Testing, Syphilis Testing, Gonorrhea Testing, Herpes Simplex Virus Testing, Human Papilloma Virus Testing, Human Immunodeficiency Virus Testing, Chancroid Testing, Other Types
2) By Location Of Testing: Laboratory Testing, Point Of Care (PoC) Testing
3) By End-User: Hospitals And Clinics, Diagnostic Centers, Homecare

Major Driver - Surging Global Prevalence Of Stds Sparks Momentum In The Std Diagnostics Market
The growing prevalence of STDs is driving the STD diagnostics market forward. STDs (sexually transmitted diseases) are infectious diseases that are transmitted from an infected person to a normal person through sexual contact. The STD diagnostics provide an efficient analysis and testing of this infection. For instance, in 2022, according to the World Health Organization (WHO), an international agency of the United Nations focusing on improving international public health, more than 1 million sexually transmitted infections are acquired every day globally. In addition, there are about 374 million new infections each year, with 1 of 4 STDs, chlamydia, gonorrhea, syphilis, and trichomoniasis. As a result, the rising prevalence of STDs propels the STD diagnostics market.

Competitive Landscape:
Major companies operating in the std diagnostics market report are Siemens AG, Abbott Laboratories, Qiagen Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., Bio-Rad Laboratories Inc., Becton Dickinson and Company, Thermo Fisher Scientific Inc., Biocartis NV, Trinity Biotech plc, Binx Health Inc., Lybrate Inc., NOWDiagnostics Inc., Alere Inc., Atlas Genetics Ltd., BioFire Diagnostics LLC, BioMérieux SA, Chembio Diagnostic Systems Inc., Corgenix Medical Corporation, Creative Diagnostics, Curetis AG, Daktari Diagnostics, Enzo Biochem Inc., Fujirebio Diagnostics Inc., GenePOC Inc., GenMark Diagnostics Inc., Grifols Diagnostic Solutions Inc., Hain Lifescience GmbH, InDevR Inc., Inflammatix Inc., Karius Inc., Luminex Corporation, Meridian Bioscience Inc., Mesa Biotech Inc., Mobidiag Oy

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/std-diagnostics-global-market-report

Top Trend - Advancements In Testing Technologies Drive Market Growth
The advancement in STD diagnostics is a key trend in STD diagnostic market. Major players are upgrading the testing facilities and techniques to provide a better and fast diagnosis of sexually transmitted diseases. For instance, in May 2022, BD (Becton, Dickinson, and Company), a US-based medical technology company launched a fully automated, high-throughput infectious disease molecular diagnostics platform, known as BD CORTM MX/PX System. This platform unifies and automates the molecular laboratory workflow, from sample processing to diagnostic test results. The first test made accessible on the new platform is the BD CTGCTV2 molecular assay, which is a single test that can identify the three most common non-viral STIs (sexually transmitted infections): Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), and Trichomonas vaginalis (TV).

The Table Of Content For The Market Report Include:
1. Executive Summary
2. STD Diagnostics Market Characteristics
3. STD Diagnostics Market Trends And Strategies
4. STD Diagnostics Market - Macro Economic Scenario
5. STD Diagnostics Market Size And Growth
…..
27. STD Diagnostics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model"

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.